3.0.0 7556 2023-01-11T13:45:58Z 2023-01-11T13:45:58Z House HR 2020-07-09 116 [Congressional Record Volume 166, Number 124 (Thursday, July 9, 2020)][House]From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]By Mr. NUNES:H.R. 7556.Congress has the power to enact this legislation pursuantto the following:Clause 1 of Section 8 of Article I of the Constitution ofthe United States[Page H3078]]]> hswm00 Ways and Means Committee House Standing Referred to 2020-07-09T18:05:20Z 116 14 HR 2020-11-02 Referred to the Subcommittee on Railroads, Pipelines, and Hazardous Materials. Related bill CRS 2020-07-09 Referred to the House Committee on Ways and Means. IntroReferral H11100 2 House floor actions hswm00 Ways and Means Committee 2020-07-09 Introduced in House IntroReferral Intro-H 9 Library of Congress 2020-07-09 Introduced in House IntroReferral 1000 9 Library of Congress N000181 Rep. Nunes, Devin [R-CA-22] Devin Nunes R CA 22 N Taxation Chemical and biological weapons Drug therapy Emergency medical services and trauma care Hazardous wastes and toxic substances Health technology, devices, supplies Income tax credits Infectious and parasitic diseases Medical research Medical tests and diagnostic methods Nuclear weapons Research and development Small business Taxation

00 2020-07-09 Introduced in House 2020-08-07T13:29:01Z This bill allows certain small businesses whose gross receipts do not exceed $1 million a refundable portion of the tax credit for increasing research activities if such businesses are engaging in specified medical research. It defines specified medical research as any qualified research with respect to qualified countermeasures. A qualified countermeasure is a drug, biological product, or device that is determined to be a priority (1) to diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; (2) to diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device; or (3) is a product or technology intended to enhance the use or effect of a drug, biological product, or device.

]]>

Display Title Official Title as Introduced Introduced in House IH Introduced in House 2020-07-09T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116hr7556ih/xml/BILLS-116hr7556ih.xml 2020-07-09 Referred to the House Committee on Ways and Means. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.